Facioscapulohumeral Muscular Dystrophy (FSHD)

Facioscapulohumeral muscular dystrophy (FSHD) is the third most common muscular dystrophy after DMD and myotonic dystrophy, affecting approximately 1 in 8,333 people regardless of sex. Unlike the dystrophinopathies, FSHD follows autosomal dominant inheritance and has a distinct — often puzzling — epigenetic mechanism: inappropriate reactivation of the embryonic DUX4 retrogene in skeletal muscle through partial loss of D4Z4 repeat-mediated chromatin repression at chromosome 4q35. FSHD's hallmark is a characteristic pattern of weakness that is both highly specific in distribution and strikingly asymmetric — facial weakness, periscapular weakness causing scapular winging, and humeral weakness, often with foot drop from tibialis anterior involvement — making it one of the more recognizable muscular dystrophies once the examining physician knows what to look for.

Table of Contents

  1. Epigenetic Mechanism: D4Z4 and DUX4
  2. FSHD1 versus FSHD2
  3. Epidemiology and Genetics
  4. Clinical Hallmarks and Distinctive Signs
  5. Clinical Spectrum and Natural History
  6. Extramuscular Features
  7. Diagnosis
  8. Management
  9. Key Research Papers

Epigenetic Mechanism: D4Z4 and DUX4

FSHD arises from a failure of epigenetic silencing at a repetitive chromosomal locus, allowing expression of a gene that should remain silent in adult muscle. Understanding this mechanism is essential for understanding why FSHD genetics differs so fundamentally from most other inherited muscle diseases.

The D4Z4 macrosatellite repeat array is located at the subtelomeric region of chromosome 4q35 (and a nearly identical array exists at 10q26). Each D4Z4 unit is approximately 3.3 kilobases in length. Healthy individuals carry between 11 and 100 repeat units on each chromosome 4. In normal somatic tissues, including adult skeletal muscle, the D4Z4 array is epigenetically silenced — maintained in a compact, heterochromatic state through DNA methylation and repressive histone modifications that prevent transcription of sequences embedded within each repeat unit.

Each D4Z4 unit encodes the DUX4 retrogene — a double-homeodomain transcription factor that is normally expressed only during early embryogenesis (the cleavage stage, in morula and blastocyst) and in germline tissue. DUX4 protein acts as a pioneer transcription factor in early development, activating programs of gene expression that are appropriate for the embryo but entirely inappropriate for differentiated adult skeletal muscle. In normal somatic cells, including mature muscle fibers, DUX4 remains silenced.

The FSHD disease mechanism centers on failure of this silencing in muscle. When D4Z4 chromatin becomes insufficiently repressed — either because there are too few repeat units (FSHD1) or because epigenetic repressor machinery is lost (FSHD2) — the DUX4 gene within the most telomeric D4Z4 unit can be transcribed in muscle cells. DUX4 protein then activates a cascade of germ-cell and early embryonic genes inappropriate for muscle, simultaneously suppressing myogenic differentiation programs, generating oxidative stress, and triggering apoptosis in muscle fibers. Even low-level sporadic DUX4 expression in a small fraction of muscle nuclei appears sufficient to cause cumulative muscle damage over time.

A critical additional requirement is the 4qA permissive haplotype. FSHD occurs only when the contracted or hypomethylated D4Z4 array sits on a chromosome carrying the 4qA haplotype. The 4qA haplotype provides a functional polyadenylation signal (pLAM) immediately distal to the last D4Z4 unit that stabilizes DUX4 mRNA transcribed from that terminal unit, allowing translation into DUX4 protein. The 4qB allele lacks this polyadenylation signal, so even if D4Z4 is contracted or hypomethylated on a 4qB chromosome, the resulting DUX4 transcripts are unstable and no DUX4 protein is produced — explaining why 4qB alleles do not cause disease despite array contraction.

The chromosome 10q26 D4Z4 array similarly lacks a permissive polyadenylation signal distal to its last D4Z4 unit. Contractions at 10q26 therefore do not cause FSHD. However, because the 4q35 and 10q26 arrays are highly homologous, molecular probes and sequencing methods can cross-hybridize between the two loci, which historically complicated Southern blot sizing and remains a technical challenge in clinical genetic testing.

Back to Table of Contents

FSHD1 versus FSHD2

FSHD is genetically heterogeneous, with two molecularly distinct forms sharing the same final common pathway — insufficient D4Z4 repression leading to DUX4 expression in muscle on a permissive 4qA background.

FSHD1 accounts for approximately 95% of cases. It results from contraction of the D4Z4 repeat array on chromosome 4q35 to 10 or fewer repeat units (the normal minimum is 11). The contracted array retains insufficient chromatin to maintain full epigenetic silencing, allowing DUX4 transcription in muscle. FSHD1 follows autosomal dominant inheritance — a single contracted 4qA allele is sufficient to cause disease. De novo mutations (new contractions arising in a single generation, not inherited from an affected parent) account for 10–30% of FSHD1 cases, a remarkably high rate for a dominant disorder, reflecting the instability of the D4Z4 repeat array during meiosis. There is a rough inverse correlation between repeat number and severity: alleles with 1–3 repeat units are associated with typically severe or infantile-onset disease, while alleles with 7–10 repeats often produce mild, late-onset, or subclinical disease.

FSHD2 accounts for approximately 5% of cases and results from loss-of-function mutations in the SMCHD1 gene (Structural Maintenance of Chromosomes Hinge Domain 1). SMCHD1 is an epigenetic repressor that normally contributes to maintaining the D4Z4 array in its silenced heterochromatic state. When SMCHD1 function is lost, D4Z4 becomes hypomethylated and transcriptionally de-repressed despite having a normal number of repeat units (11 or more). FSHD2 is autosomal dominant through the SMCHD1 mutation but requires the coincidence of a permissive 4qA allele at chromosome 4q35 — making it effectively a digenic condition. Because the D4Z4 array itself appears normal in size on standard Southern blot, FSHD2 can be missed if SMCHD1 testing and D4Z4 methylation analysis are not specifically requested.

A particularly severe subgroup are FSHD2+ patients who carry both an SMCHD1 loss-of-function mutation and a borderline D4Z4 contraction (often 8–10 repeats). The combined effect of reduced repeat number and reduced epigenetic repressor activity produces greater D4Z4 de-repression than either alone, and these patients are often among the most severely affected.

Clinically, FSHD1 and FSHD2 are indistinguishable. The same muscle groups are affected in the same distribution, the same extramuscular features may occur, and the natural history is comparable. The distinction is entirely molecular and has implications for genetic counseling (SMCHD1 mutations carry their own inheritance pattern) and emerging therapies targeting DUX4 expression.

Rarer causes of D4Z4 hypomethylation and FSHD-like disease have been identified, including mutations in DNMT3B (a DNA methyltransferase) and LRIF1 (a D4Z4-associated repressor). These account for a very small number of cases collectively.

Back to Table of Contents

Epidemiology and Genetics

FSHD has a worldwide prevalence of approximately 1 in 8,333 people, making it the third most common inherited muscular dystrophy globally. Extrapolating from prevalence data, approximately 870,000 individuals worldwide are affected, including an estimated 40,000 in the United States. These figures likely underestimate the true burden because 20–30% of individuals carrying a disease-causing D4Z4 contraction or SMCHD1 mutation have no clinical symptoms and remain undiagnosed unless examined specifically or identified through family cascade testing.

Among the muscular dystrophies, FSHD ranks third in overall prevalence after Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1, and it is the most common autosomal dominant muscular dystrophy. Population-based studies from the Netherlands — one of the most rigorously studied populations — have confirmed a minimum prevalence of approximately 12 per 100,000, with higher estimates when mildly affected or asymptomatic family members are included.

FSHD affects males and females in equal numbers, consistent with autosomal dominant inheritance. However, males tend to experience more severe clinical disease than females — a sex effect that has been observed across multiple studies and may reflect testosterone-mediated enhancement of DUX4 expression or differential muscle regenerative capacity. Females with FSHD are more likely to be in the asymptomatic carrier category.

Age of onset is extremely variable, ranging from the neonatal period (in very severe cases with very short D4Z4 arrays) to the sixth or seventh decade of life. Most patients become aware of symptoms in their teens or twenties, often attributing early scapular winging or difficulty raising their arms to sports injuries or postural issues. A family history of similar muscle problems — particularly an affected parent, sibling, or more distant relative with scapular winging or facial weakness — is an important diagnostic clue, though de novo mutations mean that 10–30% of FSHD1 patients have no known affected relative.

The high rate of de novo D4Z4 contractions distinguishes FSHD genetics from most other dominant disorders. Meiotic instability at the D4Z4 locus is well-documented, and somatic mosaicism (where the D4Z4 contraction occurred post-fertilization, resulting in some cells with a normal array and others with the contraction) has been documented in some patients, often associated with milder phenotype and reduced penetrance to offspring.

Back to Table of Contents

Clinical Hallmarks and Distinctive Signs

FSHD has one of the most distinctive and recognizable clinical signatures of any muscular dystrophy when the characteristic combination of features is present. The key to diagnosis is knowing the specific pattern and, crucially, looking for it actively — many features are subtle and patients often do not spontaneously report them.

Facial weakness is present in the majority of patients and is often the earliest sign, though frequently unrecognized by patients and their families. The orbicularis oculi is affected, producing inability to close the eyes tightly — patients cannot resist the examiner's attempt to open their eyelids, and the eyes do not fully close during sleep (lagophthalmos). Orbicularis oris weakness prevents pursing the lips, whistling, or puffing the cheeks. Zygomaticus weakness produces a characteristic transverse ("horizontal") smile — the corners of the mouth do not rise normally, giving a flat, wide grin rather than the normal upward-curving smile. Frontalis weakness impairs raising the eyebrows. Patients are often unaware of their facial weakness; close family members sometimes notice first, describing a change in facial expression over years.

Scapular winging is the most visually dramatic finding and the most frequently described feature. Weakness of the serratus anterior, lower and middle trapezius, and rhomboids causes the scapulae to lose their normal articulation against the posterior chest wall. The scapulae ride superiorly and rotate outward, with medial borders and inferior angles winging prominently away from the thorax when the patient attempts to raise their arms ("flying scapula" sign). The shoulders rotate forward, giving a rounded-shoulder posture. Patients cannot raise their arms above head height because the scapular stabilizers that normally anchor the scapula against the chest wall during arm elevation are too weak — even though the deltoid may be largely preserved. This disconnect — preserved deltoid strength but inability to elevate the arm — is diagnostically important.

Humeral weakness follows a selective pattern that complements the scapular abnormality. The biceps and triceps are preferentially affected while the deltoid is relatively spared. This produces an arm that looks normal at the shoulder (deltoid bulk preserved) but fails at the elbow — a pattern not seen in most other neuromuscular disorders. Over time, the biceps and triceps may atrophy visibly while the deltoid remains prominent.

Foot drop from tibialis anterior weakness is present in a substantial proportion of patients and is an unusual feature for a muscular dystrophy. Most MDs affect proximal muscles early and distal muscles later; FSHD can produce significant foot drop relatively early in the disease course, causing a steppage gait and increased fall risk. The foot drop is typically asymmetric, consistent with the overall asymmetric pattern of FSHD.

Asymmetry is perhaps the single most diagnostically useful characteristic feature of FSHD and distinguishes it from virtually every other hereditary muscle disease. Weakness is typically more pronounced on one side than the other, sometimes markedly so — patients may have profound scapular winging on the right with only mild winging on the left, or foot drop on one side only. Right-sided predominance has been observed in most clinical series, though the mechanism is unknown. The degree of asymmetry seen in FSHD is unusual enough that its presence should always prompt consideration of the diagnosis, even in the absence of a clear family history.

Beevor's sign is a classic and highly specific examination finding in FSHD. When the patient flexes the neck against resistance (or attempts to sit up from the supine position), the navel moves upward (cranially) rather than remaining stationary. This occurs because the lower rectus abdominis (below the umbilicus) is weaker than the upper rectus abdominis — the upper portion anchors in place while the lower portion gives way, pulling the navel upward. Beevor's sign was originally described in spinal cord lesions at T10 but has since become particularly associated with FSHD, where it reflects the characteristic truncal muscle involvement pattern.

Selective muscle sparing is as important as selective muscle involvement. Extraocular muscles are uniformly spared in FSHD (unlike myotonic dystrophy and oculopharyngeal muscular dystrophy). Pharyngeal and palatal muscles are spared (unlike oculopharyngeal MD). The cardiac muscle is characteristically spared, with no cardiomyopathy (unlike DMD, BMD, and EDMD). The diaphragm is also typically spared, and respiratory failure is rare except in the most severely affected, wheelchair-dependent patients with marked truncal and intercostal weakness.

Back to Table of Contents

Clinical Spectrum and Natural History

The clinical presentation of FSHD spans an exceptionally wide spectrum, from individuals who are entirely asymptomatic throughout life (discovered only when a more severely affected family member is diagnosed and relatives are screened) to patients with severe childhood-onset disease requiring a wheelchair before adulthood.

The natural history of FSHD is typically characterized by a slow, stepwise progression interspersed with long periods of relative stability. Unlike DMD, which follows a predictable trajectory, FSHD progression is highly individual and difficult to predict at the outset. Some patients remain mildly affected for decades after diagnosis; others experience meaningful functional decline over years. Periods of apparent stability may be punctuated by subacute worsening episodes, sometimes temporally associated with prolonged immobility (post-surgical bed rest, illness requiring hospitalization), significant weight gain, or — in some patients — no identifiable precipitant.

The anatomical progression pattern tends to follow a rostrocaudal gradient, though with considerable individual variation. Facial weakness is often present earliest (though recognized late). Shoulder-girdle and periscapular weakness typically becomes functionally limiting next — inability to raise the arms above the head is often the first symptom that prompts medical evaluation. Humeral (biceps, triceps) weakness follows. Abdominal muscle weakness — contributing to protuberant abdomen, exaggerated lumbar lordosis, and Beevor's sign — becomes apparent in many patients. Foot-ankle weakness (tibialis anterior, peroneal muscles) causing foot drop occurs in a substantial proportion. Hip-girdle (pelvic girdle) involvement develops later in approximately 60% of patients and correlates with eventual loss of independent ambulation.

Wheelchair dependence occurs in 7–21% of FSHD patients across published series. The strongest predictors of wheelchair use are a very short D4Z4 array (1–3 repeat units in FSHD1), onset of symptoms before age 10, and development of pelvic girdle weakness. Patients with larger D4Z4 arrays (8–10 units) rarely reach wheelchair dependence.

Infantile FSHD represents the severe end of the spectrum and accounts for a small but important minority. Onset occurs from birth to age 5, usually associated with very short D4Z4 arrays (1–4 units, often de novo). These patients have more severe and widespread weakness, progress more rapidly, and have higher rates of extramuscular complications including sensorineural hearing loss, retinal vascular disease (Coats disease), and — in the most severe cases — intellectual disability or epilepsy. Intellectual involvement in infantile FSHD is rare but documented.

Pain is a major but historically underrecognized burden in FSHD. Chronic musculoskeletal pain affects approximately 75% of patients with symptomatic disease and often exceeds the functional disability as the chief quality-of-life impairment. Pain is multifactorial — abnormal joint mechanics from scapular winging and muscle imbalances, compensatory postural strain, and possibly DUX4-mediated peripheral sensitization pathways. Pain management is an essential component of FSHD care and requires active inquiry, as many patients do not report it spontaneously unless asked.

It bears emphasis that the 20–30% of mutation carriers who remain entirely asymptomatic or subclinical throughout their lives are a genuine feature of the disease, not an artifact of ascertainment. This high rate of subclinical disease complicates genetic counseling — a parent with a D4Z4 contraction who has never noticed any weakness may have children who are far more severely affected.

Back to Table of Contents

Extramuscular Features

Although FSHD is primarily a skeletal muscle disease, extramuscular features are well-documented and clinically important. Several require active screening because they can cause irreversible end-organ damage if undetected.

Sensorineural hearing loss occurs in approximately 25% of FSHD patients, making it the most common extramuscular feature. It is typically high-frequency and usually mild to moderate in severity, though it can be more pronounced in patients with infantile FSHD and very short D4Z4 arrays. Many patients are unaware of their hearing loss before formal audiometric testing. Audiologic screening is recommended at the time of FSHD diagnosis and periodically thereafter, particularly in children.

Coats disease (exudative retinopathy) is a retinal vascular abnormality characterized by telangiectatic retinal vessels that leak fluid, causing progressive exudative retinal detachment if untreated. Coats disease occurs in 1–3% of FSHD patients overall but is substantially more common in infantile FSHD with very short D4Z4 arrays, where some series report rates up to 60% in severely affected children. Coats disease in FSHD affects males and females equally (unlike isolated Coats disease, which is male-predominant), is often asymptomatic in early stages, and can lead to permanent visual impairment or blindness if not identified and treated before exudation causes retinal detachment. Annual funduscopic examination by an experienced ophthalmologist is standard of care for all FSHD patients, with increased frequency and urgency in those with infantile-onset disease or very short arrays.

Cardiac involvement is characteristically absent in FSHD — this distinguishes it from DMD, BMD, and Emery-Dreifuss muscular dystrophy (EDMD), where cardiomyopathy and/or arrhythmias are major causes of morbidity and mortality. Occasional conduction abnormalities have been reported in severely affected, long-standing FSHD patients, but these are uncommon and generally not clinically significant. The development of significant cardiac disease in a patient with suspected FSHD should prompt reconsideration of the diagnosis.

Respiratory involvement is also typically spared in FSHD until late in the disease course. The diaphragm is not preferentially targeted by FSHD, and respiratory failure is rare except in the most severely affected wheelchair-dependent patients who develop progressive truncal and intercostal muscle weakness over decades. Annual pulmonary function testing is recommended in non-ambulatory patients, with nocturnal non-invasive ventilation (NIV) initiated when forced vital capacity falls below 50% predicted or when symptoms of nocturnal hypoventilation are present.

Abdominal wall weakness is a nearly universal feature in symptomatic FSHD. Selective weakness of the lower abdominal musculature (below the umbilicus) produces the characteristic Beevor's sign described above, as well as protuberant abdomen, exaggerated lumbar lordosis, and postural back pain. Anterior abdominal wall hernias have been reported in some patients as a consequence of chronic abdominal muscle weakness.

Cognitive and central nervous system involvement is not a feature of typical FSHD. Intelligence is normal in the vast majority of patients. Rare case reports of intellectual disability and epilepsy in the setting of infantile FSHD with extremely short D4Z4 arrays (1–2 units) exist, but these cases likely represent the extreme severe end of a continuum rather than a typical FSHD feature. The absence of cognitive involvement is clinically useful in distinguishing FSHD from myotonic dystrophy type 1, which shares some phenotypic overlap and also produces cognitive and personality changes.

Back to Table of Contents

Diagnosis

FSHD diagnosis rests on three pillars: a characteristic clinical pattern, molecular genetic confirmation, and ancillary investigations to complete the clinical picture and screen for extramuscular complications.

Clinical diagnosis begins with recognition of the distinctive phenotype: facial weakness (orbicularis oculi and oris involvement), periscapular weakness with scapular winging, selective humeral weakness with relative deltoid sparing, the profound asymmetry that distinguishes FSHD from all other hereditary muscle diseases, and Beevor's sign on the neurological examination. Foot drop from tibialis anterior weakness is an additional clue. A positive family history consistent with autosomal dominant inheritance supports the diagnosis, though de novo cases are common enough that its absence does not argue against FSHD.

Serum creatine kinase (CK) is normal or mildly elevated in FSHD — typically less than three times the upper limit of normal. This is in sharp contrast to DMD and BMD, where CK is massively elevated (often 50–100× ULN in DMD). Mildly higher CK values may be seen during inflammatory phases of FSHD. A markedly elevated CK in a patient with suspected FSHD should prompt consideration of an alternative or additional diagnosis.

Genetic testing is definitive and is required for confident diagnosis. The critical point is that standard clinical exome sequencing panels, MLPA arrays, and most next-generation sequencing-based tests cannot size or identify D4Z4 repeat contractions at 4q35. The gold standard diagnostic test is Southern blot analysis using a probe (p13E-11) that hybridizes to the D4Z4 region, combined with restriction enzyme digestion and haplotyping to determine the 4qA versus 4qB status. This test must be sent to a laboratory with specific expertise in FSHD molecular diagnosis. The result provides the repeat unit count on the 4q35 allele and confirms the permissive 4qA haplotype. Molecular combing is an emerging alternative technology that can provide similar information with potentially higher accuracy for borderline cases. If Southern blot shows a normal repeat number (more than 10 units) but clinical suspicion for FSHD remains high, D4Z4 methylation analysis should be performed — hypomethylation at a normal-size array indicates FSHD2 — followed by sequencing of SMCHD1 if hypomethylation is confirmed.

Muscle MRI has become an increasingly important tool in FSHD diagnosis and monitoring. T1 fat-suppressed sequences demonstrate selective fatty infiltration in the characteristic distribution — periscapular muscles (serratus anterior, trapezius, rhomboids), humeral muscles (biceps, triceps with relative deltoid sparing), and tibialis anterior — that mirrors the clinical weakness pattern. T2-STIR sequences detect active muscle edema and inflammation in early or active disease phases, sometimes revealing affected muscles before clinical weakness is detectable. Muscle MRI is particularly useful when the clinical picture is atypical, when quantifying disease burden for research or trials, and when planning surgical interventions.

Electromyography (EMG) shows myopathic motor unit potentials in affected muscles and normal nerve conduction studies — consistent with a primary muscle disease. Occasional inflammatory changes (complex repetitive discharges, fibrillation potentials) may be seen, reflecting the inflammatory component of active FSHD. EMG is rarely needed when the diagnosis is made clinically and confirmed genetically, but can be useful when the diagnosis is uncertain.

Muscle biopsy shows nonspecific myopathic features — variation in fiber size, internal nuclei, occasional fibers undergoing necrosis and regeneration, and sometimes an inflammatory infiltrate. Biopsy findings are not diagnostic of FSHD and can mimic inflammatory myopathy in active disease phases. Given the availability of definitive genetic testing, muscle biopsy is generally not required in patients with a classic clinical picture and confirmatory genetic results.

Extramuscular screening should be completed at diagnosis: funduscopic ophthalmologic examination for Coats disease retinopathy, formal audiometry for sensorineural hearing loss, and pulmonary function testing (especially in non-ambulatory patients). Cardiac evaluation is not routinely required unless symptoms suggest involvement, given the characteristic sparing of cardiac muscle in FSHD.

The differential diagnosis includes myotonic dystrophy type 1 (can have facial weakness, but myotonia, cognitive involvement, and specific genetics distinguish it), oculopharyngeal muscular dystrophy (late-onset ptosis and dysphagia, not scapular winging), inflammatory myopathies including polymyositis (elevated CK, subacute onset, no family history, responds to immunosuppression), scapuloperoneal muscular dystrophy, Emery-Dreifuss MD (humeroperoneal weakness and contractures plus cardiac involvement), and limb-girdle MDs (generally symmetric and lacking facial involvement).

Back to Table of Contents

Management

As of 2025, there is no approved disease-modifying therapy for FSHD. Management is currently supportive and symptomatic, focused on preserving function, preventing complications, and managing pain. Research into DUX4 inhibition has produced early-stage evidence and ongoing trials that represent the most promising near-term avenue for disease modification.

Disease-modifying therapy pipeline centers on reducing DUX4 expression or its downstream effects in muscle. Losmapimod, a selective p38α/β MAPK inhibitor, reduces expression of DUX4 target genes in muscle. The ReDUX4 phase 2 randomized controlled trial demonstrated that losmapimod was safe and well-tolerated, with secondary endpoints (DUX4 target gene biomarkers and some functional measures) meeting statistical significance, though the primary endpoint (electrical impedance myography, EFA) did not reach significance. Phase 3 planning is ongoing. Additional pipeline agents include antisense oligonucleotides (ASOs) targeting DUX4 mRNA directly, small-molecule epigenetic approaches to re-silence D4Z4, and RNA interference-based strategies. Gene therapy for FSHD is more complex than for DMD given the epigenetic rather than straightforward protein-coding nature of the mutation.

Scapulothoracic fusion surgery (scapular fixation) is the most established surgical intervention for FSHD and can meaningfully improve function. The procedure fixates the scapula firmly to the posterior rib cage, restoring a stable fulcrum for arm elevation. The result is improved active arm elevation — patients who cannot raise their arm above the shoulder preoperatively may achieve overhead reach postoperatively. Appropriate patient selection is critical: candidates should have significant periscapular weakness with scapular winging, preserved deltoid strength, and functional elbow flexors. Patients with very severe generalized weakness are not good surgical candidates. Evidence comes from observational series and patient-reported outcomes rather than randomized trials, but the functional benefit is clinically meaningful for well-selected patients.

Scapular orthoses (bracing devices that mechanically stabilize the scapula) offer a non-surgical alternative. Functional benefit is generally less than surgical fixation, but some patients experience improved arm elevation and reduced fatigue with well-fitted orthoses. Bracing is particularly useful as a preoperative trial to predict likely benefit from surgical fixation, or for patients who decline or are not candidates for surgery.

Ankle-foot orthoses (AFOs) address foot drop from tibialis anterior weakness, improving gait safety, reducing fall risk, and reducing energy expenditure during walking. Custom AFOs are preferred for fit and function.

Pain management is a central component of FSHD care that is frequently underaddressed. A multidisciplinary approach is most effective. NSAIDs may provide modest benefit for musculoskeletal pain. Low-dose tricyclic antidepressants (amitriptyline) or serotonin-norepinephrine reuptake inhibitors (duloxetine) can help with chronic pain syndromes. Aquatic physical therapy is particularly well-tolerated and can address both pain and deconditioning. Opioid analgesics carry risks of dependence and side effects that generally outweigh benefits in this population and should be avoided or minimized.

Exercise and physical therapy are safe and beneficial in FSHD, despite early concerns that exercise might accelerate muscle damage. Aerobic exercise — particularly swimming and aquatic therapy, which reduce gravitational and eccentric loading — is well-tolerated and improves cardiovascular fitness and quality of life. Strength training with moderate resistance is reasonable; eccentric overload exercises (particularly loaded downhill walking or resisted lengthening contractions) should be approached with caution as they may transiently increase muscle damage markers. Occupational therapy addresses adaptive equipment needs and upper extremity functional optimization.

Ophthalmologic surveillance requires annual funduscopic examination by an ophthalmologist familiar with Coats disease. When retinal vascular telangiectasias or early exudation is identified, treatment with laser photocoagulation or intravitreal anti-VEGF injections should be initiated promptly to prevent progression to exudative retinal detachment and permanent vision loss. Children with infantile FSHD require particularly close ophthalmologic monitoring.

Audiologic care: Documented sensorineural hearing loss should be fitted with hearing aids when thresholds reach levels that impair communication. Regular audiometric monitoring is appropriate, with increased frequency in individuals with infantile-onset disease.

Respiratory monitoring: Annual spirometry and pulmonary function tests in non-ambulatory patients. Nocturnal non-invasive ventilation (NIV — CPAP or bilevel PAP) is initiated when forced vital capacity falls below 50% predicted, when arterial blood gas demonstrates hypercapnia, or when symptoms of nocturnal hypoventilation (morning headache, daytime hypersomnolence, nocturnal dyspnea) are present.

Genetic counseling is an essential component of FSHD management. FSHD1 and FSHD2 are both autosomal dominant — each child of an affected individual has a 50% probability of inheriting the mutation. However, penetrance is incomplete and phenotype is highly variable, making prognosis for any individual offspring impossible to predict from the mutation alone. Prenatal genetic testing (chorionic villus sampling or amniocentesis with D4Z4 sizing) is technically feasible. Preimplantation genetic testing (PGT) in the setting of IVF is an option for couples wishing to avoid transmitting FSHD. Cascade testing of at-risk family members is recommended to identify asymptomatic mutation carriers who may benefit from surveillance for extramuscular complications.

Back to Table of Contents

Key Research Papers

The following peer-reviewed publications represent landmark and foundational research in the understanding, genetics, and management of facioscapulohumeral muscular dystrophy.

  1. Deenen JC et al. "Population-based incidence and prevalence of facioscapulohumeral dystrophy." Neurology. 2014;83(12):1056–9. PMID: 25122204
  2. Lemmers RJ et al. "A unifying genetic model for facioscapulohumeral muscular dystrophy." Science. 2010;329(5999):1650–3. PMID: 20724583
  3. van Deutekom JC et al. "FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit." Hum Mol Genet. 1993;2(12):2037–42. PMID: 8111371
  4. Wijmenga C et al. "Location of facioscapulohumeral muscular dystrophy gene on chromosome 4." Lancet. 1990;336(8716):651–3. PMID: 1975852
  5. Gabriëls J et al. "Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element." Gene. 1999;236(1):25–32. PMID: 10433960
  6. Sacconi S et al. "The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1." Am J Hum Genet. 2013;93(4):744–51. PMID: 24075186
  7. Statland JM et al. "Chromatin hypomethylation influences clinical expression in facioscapulohumeral muscular dystrophy and constitutes a therapeutic target." J Neuropathol Exp Neurol. 2015;74(5):411–22. PMID: 25853694
  8. Tawil R et al. "Evidence-based guideline summary: evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy." Neurology. 2015;85(4):357–64. PMID: 26078397
  9. Mul K et al. "Phenotypic spectrum of facioscapulohumeral muscular dystrophy." Neurology. 2019;93(11):e1108–e1116. PMID: 31399546
  10. Lemmers RJ et al. "Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2." Nat Genet. 2012;44(12):1370–4. PMID: 23143600
  11. Padberg GW et al. "On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy." Muscle Nerve Suppl. 1995;2:S73–80. PMID: 8538656
  12. Statland J et al. "Scapular fixation in facioscapulohumeral muscular dystrophy." Cochrane Database Syst Rev. 2010;(3):CD007621. PMID: 20238356

Back to Table of Contents

Connections